莫诺帕制药

US · MNPR #3671 按市值排名上市于 2019

69.27 -2.53 -3.52%

实时 - 追踪5344个代码 - 心跳于496秒前 · 2026-10-16 20:02

✦ 量化股权信号计算方式说明

减持

最近一期（2026/Q3）披露持股的机构数量增加了1家。
机构持股总比例下降了0.2个百分点。

机构持股

机构持股比例: 109.11% -0.18pp
机构数量: 114 +1
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund47.10%

Hedge Fund24.02%

VC/PE Fund20.69%

Private Company8.64%

Public Company8.44%

Individual/Insider7.26%

Government Pension Fund0.14%

主要股东截至 2026-06-30

Janus Henderson Group plc 19.55% · 1.31M 股

RA Capital Management, L.P. 9.94% · 667.21K 股

Tactic Pharma LLC 8.46% · 567.58K 股

AstraZeneca PLC 7.79% · 522.67K 股

BlackRock 5.20% · 348.82K 股

Deerfield Management Company, L.P. 4.82% · 323.75K 股

Saturn V Capital Management LP 4.65% · 311.98K 股

Artal Group S.A. 4.02% · 270.12K 股

Vanguard Capital Management, LLC 3.55% · 237.99K 股

ADAR1 Capital Management, LLC 3.24% · 217.60K 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 31次买入 · 19次卖出

姓名	职务	持股比例
Chandler Robinson	Chief Executive Officer	2.50%
Michael Brown	Independent Director	1.58%
Andrew Cittadine	Chief Operating Officer	0.86%
Christopher Starr	Independent Executive Chairman of the Board	0.22%
Lavina Talukdar	Director	0.21%
Kim Tsuchimoto	CFO, Secretary, Treasurer & Director	0.17%
Arthur Klausner	Independent Director	0.13%
Raymond Anderson	Independent Director	0.08%
Patrice Rioux	Acting Chief Medical Officer	0.08%
Quan Vu	CFO, Principal accounting officer & Principal financial officer	0.04%

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-09-30	Christopher Starr	Independent Executive Chairman of the Board	Derivative Exercise and Sale	-8,400	$0.01–79.67
2026-09-29	Andrew Cittadine	Chief Operating Officer	Derivative Exercise and Sale	-1,944	$79.67
2026-09-29	Andrew Cittadine	Chief Operating Officer	Derivative Exercise and Retained	+2,440	--
2026-09-29	Chandler Robinson	Chief Executive Officer	Derivative Exercise and Sale	-4,344	$79.67
2026-09-29	Chandler Robinson	Chief Executive Officer	Derivative Exercise and Retained	+5,457	--
2026-09-29	Quan Vu	CFO, Principal accounting officer & Principal financial officer	Derivative Exercise and Sale	-180	$79.67
2026-09-29	Quan Vu	CFO, Principal accounting officer & Principal financial officer	Derivative Exercise and Retained	+434	--
2026-09-23	Chandler Robinson	Chief Executive Officer	Derivative Exercise and Sale	-29,056	$14.00–89.79
2026-08-25	Patrice Rioux	Acting Chief Medical Officer	Derivative Exercise and Sale	-1	$0.01–111.26
2026-08-25	Patrice Rioux	Acting Chief Medical Officer	Other Derivative Acquisition	+1,380	$0.01
2026-08-25	Patrice Rioux	Acting Chief Medical Officer	Derivative Exercise and Retained	+1,379	$0.01
2026-08-25	Kim Tsuchimoto	CFO, Secretary, Treasurer & Director	Automatic Disposition	-4,090	$108.83–113.84
2026-08-25	Kim Tsuchimoto	CFO, Secretary, Treasurer & Director	Derivative Exercise and Sale	-4,090	$14.00–113.84
2026-08-25	Kim Tsuchimoto	CFO, Secretary, Treasurer & Director	Other Derivative Acquisition	+4,090	$14.00–30.00
2026-08-24	Raymond Anderson	Independent Director	Derivative Exercise and Sale	-3,142	$30.00–113.05
2026-08-24	Raymond Anderson	Independent Director	Other Derivative Acquisition	+3,142	$30.00
2026-07-07	Arthur Klausner	Independent Director	Intent to Sell (Form 144)	-5,000	--
2026-06-29	Andrew Cittadine	Chief Operating Officer	Derivative Exercise and Sale	-2,309	$92.59
2026-06-29	Andrew Cittadine	Chief Operating Officer	Derivative Exercise and Retained	+2,945	--
2026-06-29	Chandler Robinson	Chief Executive Officer	Derivative Exercise and Sale	-4,084	$92.59

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 20:02:16 · 仅供参考，不构成投资建议，也未考虑您的具体情况。